drugset / Trial / NCT01240941
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II Trial of MK-2206 in combination with Endocrine Therapy in patients with Hormone Receptor Breast Cancer. After the maximum tolerated dose is determined in the phase 1b trial (under a separate NCT number), efficacy will be evaluated among 17 patients.
Timeline
- Start
- 2011-02
- Primary completion
- 2012-06
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-2206 | Small molecule | — | Oral |
| Background | Exemestane | Small molecule | 25 mg | Oral |
| Background | Goserelin | Other / unclassified | 3.6 mg | Oral |